JPH01268628A - Coated solid drug - Google Patents
Coated solid drugInfo
- Publication number
- JPH01268628A JPH01268628A JP9451288A JP9451288A JPH01268628A JP H01268628 A JPH01268628 A JP H01268628A JP 9451288 A JP9451288 A JP 9451288A JP 9451288 A JP9451288 A JP 9451288A JP H01268628 A JPH01268628 A JP H01268628A
- Authority
- JP
- Japan
- Prior art keywords
- solid drug
- drug
- erythritol
- coating material
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 229940079593 drug Drugs 0.000 title claims abstract description 38
- 239000007787 solid Substances 0.000 title claims abstract description 30
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 19
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 19
- 239000011248 coating agent Substances 0.000 claims abstract description 17
- 238000000576 coating method Methods 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 14
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 claims abstract description 4
- 239000011247 coating layer Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 15
- 235000019640 taste Nutrition 0.000 abstract description 7
- 150000005846 sugar alcohols Chemical class 0.000 abstract description 5
- 150000001720 carbohydrates Chemical class 0.000 abstract description 2
- 230000006835 compression Effects 0.000 abstract description 2
- 238000007906 compression Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000004386 Erythritol Substances 0.000 description 16
- 229940009714 erythritol Drugs 0.000 description 16
- 235000019414 erythritol Nutrition 0.000 description 15
- 239000000843 powder Substances 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 239000001096 (4-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrochloride Substances 0.000 description 1
- NNKXWRRDHYTHFP-HZQSTTLBSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydron;dichloride Chemical compound Cl.Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 NNKXWRRDHYTHFP-HZQSTTLBSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 229960001811 quinine hydrochloride Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940126589 solid medicine Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】
（、） 発明の目的
（産業上の利用分野）
本発明は被覆固形薬剤、特に吸湿性や薬剤臭や薬剤味の
改善された被覆固形薬剤に関する。本明細書に記載の「
固形薬剤」とは医薬及び栄養強化剤から選ばれた薬剤で
あって、粉末や粒状や塊状等の固形状のものをいう。DETAILED DESCRIPTION OF THE INVENTION (1) Object of the Invention (Field of Industrial Application) The present invention relates to a coated solid drug, and particularly to a coated solid drug with improved hygroscopicity, drug odor, and drug taste. As described herein, “
"Solid drug" refers to a drug selected from pharmaceuticals and nutritional fortifiers, which is in solid form such as powder, granules, or lumps.
（従来の技術）
ストレプトマイシン、塩酸ピロカルビン、果糖、クエン
酸、安息香酸ナトリウム、ビタミン人、塩酸チアミンな
どの吸湿性を有する固形薬剤は、空気中に放置すると吸
湿して湿潤・液化し、化学的及び物理的変化を起し品質
保持及び取扱性等の面で種々の問題がある。そのためＫ
、これらの吸湿性薬剤の保存には包装゛のための手間と
資材や容器と費用がかかる。(Prior art) Hygroscopic solid drugs such as streptomycin, pilocarbin hydrochloride, fructose, citric acid, sodium benzoate, vitamin C, and thiamine hydrochloride absorb moisture and become wet and liquefied when left in the air, resulting in chemical and Physical changes occur and there are various problems in terms of quality maintenance and handling. Therefore K
However, storing these hygroscopic drugs requires time, materials, containers, and costs for packaging.
また、固形薬剤は、種類によっては、たとえば塩酸キニ
ーネ、カフェイン、テオフィリン、アスピリン、ダンチ
アナ末、センブリ末等の健胃剤などのように、苦味が強
かりた）、不快な臭気を有するものの場合などには、固
形薬剤の希釈、増量又は被覆等の目的でしょ糖や乳糖等
のｆａ類が使用されるが、これらの糖類はう触性及び高
力口１７ ＋＋Ｈ性の点において健康上の問題があるし
、かつしょ糖の場合には吸湿性及び酸やアルカリや加熱
による着色の点においても問題があった。In addition, depending on the type of solid drug, for example, quinine hydrochloride, caffeine, theophylline, aspirin, stomachic preparations such as Dantiana powder, Oriental herb powder, etc., solid drugs have a strong bitter taste) or have an unpleasant odor. Although FAs such as sugar and lactose are used to dilute, increase the volume, or coat solid drugs, these sugars pose health problems due to their caries properties and high strength properties. However, in the case of sucrose, there were also problems in terms of hygroscopicity and coloration due to acids, alkalis, and heating.
（発明が解決しようとする問題点）
本発明は、吸湿性や臭気や苦味等の好ましくない薬味を
有する固形薬剤を、非う触性及び低カロリー性の被覆材
で被覆して吸湿性や臭気や苦味等が改善された被覆固形
薬剤を提供しようとするものである。(Problems to be Solved by the Invention) The present invention provides a method for covering solid drugs that are hygroscopic and have undesirable tastes such as odor and bitterness with a non-cariogenic and low-calorie coating material. The purpose of the present invention is to provide a coated solid drug with improved taste and bitterness.
すなわち１本発明の被覆固形薬剤は、固形薬剤の表面に
メン−エリスリトールを主成分とする被覆材の被覆層を
形成せしめてなるものである。That is, the coated solid drug of the present invention is obtained by forming a coating layer of a coating material containing men-erythritol as a main component on the surface of a solid drug.
本発明におけるメソーエリスＩＪ ）−ルは、構造式％
式％（
で表わされる四価の糖アルコールであシ、分子量１２２
、融点１１９℃の白色結晶で、外観がしょ糖のグラニユ
ー糖に似ていて、水に溶け、非消化性（低カロリー性）
、非う触性である。メソ−エリスリトール（以下、単に
「エリスリトール」と略称する）は、天然の藻類、キノ
コ類などに含まれ、ま九日本酒、ワイン、醤油などにも
少量含まれている。その甘味の強さ及び甘味質は、パネ
ルテスト結果によれば、甘味の強さがしょ糖よりやや弱
く、ぶどう糖よりやや強く、しょ糖の約７５〜８０％の
甘味強さに相当し、口当りがしょ糖よシも甘味が残らな
い。また、エリスリ）・−ルは酸やアルカリや熱によシ
褐色に変色しないなど、化学的に安定でちる。In the present invention, mesoeris IJ)-le has the structural formula %
It is a tetravalent sugar alcohol represented by the formula % (, molecular weight 122
, a white crystal with a melting point of 119°C, similar in appearance to granulated sucrose, soluble in water, and non-digestible (low calorie).
, non-carious. Meso-erythritol (hereinafter simply referred to as "erythritol") is contained in natural algae, mushrooms, etc., and is also contained in small amounts in Japanese sake, wine, soy sauce, etc. According to panel test results, its sweetness is slightly weaker than sucrose, slightly stronger than glucose, and has about 75-80% of the sweetness of sucrose, and its taste is lower than that of sucrose. Yoshi doesn't leave a sweet taste either. In addition, erythritol is chemically stable and does not turn brown when exposed to acids, alkalis, or heat.
また、エリスリトールは、ぶどう塘を基質とする醗酵法
、ｎ−ｚ４２フィンを基質とする醗酵法、酒石酸を還元
する方法、セルロースや澱粉を過ヨウ素酸で酸化したの
ち水素添加及び加水分解する方法等の方法で製造するこ
とができる。In addition, erythritol can be produced by fermentation methods using grape tang as a substrate, fermentation methods using nz42fin as a substrate, methods of reducing tartaric acid, methods of oxidizing cellulose or starch with periodic acid, and then hydrogenating and hydrolyzing them. It can be manufactured by the following method.
本発明の被覆固形薬剤は、固形薬剤をかかるエリスリト
ールを主成分とする被覆材で被覆せしめたものであるが
、その被覆材はエリスリトールのみからなっていてもよ
いし、エリスリトールに、比較的に吸湿性の少ない糖又
は糖アルコールを比較的少量配合したものであってもよ
いし、エリスリトールに、結合剤として澱粉、ゼラチン
、カル−キシメチルセルロースナトリウム、メチルセル
ロース、ア７ビアゴム、ｔＭ！セルロース、α−セルロ
ース、プルランなどを、さらには崩壊剤とＬｌｔ粉、
カル？キシメチルセルロースカルシウム、アルギン酸な
どを、いずれも比較的に少量配、合し九ものであっても
よい。The coated solid drug of the present invention is obtained by coating a solid drug with a coating material containing erythritol as a main component. It may contain a relatively small amount of sugar or sugar alcohol with low oxidation, or erythritol may be combined with starch, gelatin, sodium carboxymethylcellulose, methylcellulose, gum avia, or tM! as a binder. Cellulose, α-cellulose, pullulan, etc., as well as disintegrants and Llt powder,
Cal? Calcium oxymethylcellulose, alginic acid, etc. may be added in relatively small amounts or in combination.
一般に、エリスリトールは比較的に化学的に安定な不活
性物質であるので、医薬や栄養強化剤に悪影響を与える
おそれがないし、下表に示すように他の糖や塘アルコー
ノＶと比較して加熱による着色が少ないし、酸やアルコ
ールによる着色も少ないし、甘味質も既述のように良好
であるし、さらに非う触性及び無カロリー性のものであ
るから、医薬や栄養強化剤の被覆材として極めて優れて
いる。In general, erythritol is a relatively chemically stable and inert substance, so there is no risk of adverse effects on medicines or nutritional fortifiers, and as shown in the table below, erythritol does not have a negative effect when heated compared to other sugars and Tong Alcono V. There is little coloration caused by acid or alcohol, and the sweetness is good as mentioned above.Furthermore, it is non-carious and non-caloric, so it is suitable for coating pharmaceuticals and nutritional fortifiers. It is extremely excellent as a material.
糖類の加熱による着色度１
傘
着色度の試験方法
各ｍ類の試料２ｇを試験管にとり、１００℃、１５０℃
又は２００℃の各温度の乾熱話中でｊｌ、５時間加熱保
持した。冷却後、８ゴの水をそれぞれ加えて混合、溶解
させ、分光光度計で４２０ｎｍ、７２０ｎｍの吸光度を
求めた。また、別にブランク試験として、加熱前の各糖
類をそれぞれ８Ｍの水に加えて混合、溶解させたものに
ついて同様に吸光度を求め、下記式により着色度を算出
した。Degree of coloration due to heating of sugars 1 Test method for degree of coloration Place 2g of each sample in a test tube at 100°C and 150°C.
Alternatively, the mixture was heated and held for 5 hours in a dry heat oven at 200°C. After cooling, 8 g of water was added to each to mix and dissolve, and the absorbance at 420 nm and 720 nm was determined using a spectrophotometer. Separately, as a blank test, each saccharide before heating was added to 8 M water, mixed and dissolved, and the absorbance was determined in the same manner, and the degree of coloration was calculated using the following formula.
着色度＝加熱後の吸光度−加熱前の吸光度（４２０ｎｍ
−７２０ｎｍ） （４２０ｎｍ−７２０ｎｒｎ）本発
明の被覆固形薬剤の製造は、種々の方法によす行なうこ
とができる。その代表的な方法としては、■固形薬剤を
核錠剤とし、エリスＩＪ ）−・ルを主剤とする被覆材
を外皮錠として用いて、有核錠剤機等で圧縮成形する方
法、■エリスＩＪ ）−ルを主剤とする被覆材の加熱融
解液を固形薬剤に噴霧又は塗布して固形薬剤を被覆する
方法、■固形薬剤にエリスリトールを主剤とする被覆材
粉末をまぶす方法があげられるが、一般的にいって■の
方法は、吸湿性や薬剤具や薬剤味の改良効果に優れてい
るので好ましい。Degree of coloring = absorbance after heating - absorbance before heating (420 nm
-720nm) (420nm-720nrn) The coated solid drug of the present invention can be produced by various methods. Typical methods include: ■ A method in which a solid drug is used as a core tablet, and a coating material containing Ellis IJ) as the main ingredient is used as an outer tablet, and compression molded using a cored tablet machine, etc.; - A method of coating a solid drug by spraying or applying a heated molten liquid of a coating material whose main ingredient is erythritol, and a method of coating a solid drug with a powder of a coating material whose main ingredient is erythritol. In particular, method (2) is preferable because it is excellent in improving hygroscopicity, drug ingredients, and drug taste.
■の方法において用いられる被覆材のエリスリトールは
、粉末状又は顆粒状で用いられる。その顆粒としては、
含水率５〜ｌＯ重ｋｋ優の工１７スリトール粉末を押出
し造粒器で顆粒状に成形したのち乾燥し九もの、又は流
動状態のエリスリトール粉末に糊料（たとえば濃度３重
量優のゼラチン水溶液や濃度３重量饅のローカストビー
ンガム水溶液）、着しくは濃度３重量％の糖や糖アルコ
ール水溶液をエリスリトール粉末に対して４〜１０重量
優程度の量噴霧しながら流動層造粒機を用いて造粒して
から乾燥し友ものなどが好ましい。Erythritol, which is the coating material used in method (2), is used in powder or granule form. The granules are
Process 17 Thritol powder with a water content of 5 to 10% by weight is extruded and formed into granules using a granulator, dried, or erythritol powder in a fluid state is mixed with a thickening agent (for example, an aqueous gelatin solution with a concentration of 3% by weight or a concentration of 3% by weight). Granulate the erythritol powder using a fluidized bed granulator while spraying an aqueous solution of locust bean gum, preferably a sugar or sugar alcohol aqueous solution with a concentration of 3% by weight, in an amount of approximately 4 to 10% by weight to the erythritol powder. It is preferable to dry it and then dry it.
（実施例等）
以下に実施例をあげてさらに詳述するが、本発明は実施
例によって限定されるものではない。(Examples, etc.) The present invention will be described in further detail with reference to Examples below, but the present invention is not limited by the Examples.
実施例１〜４
第１表に示す槙々の固形薬剤を核錠剤とし、エリスリト
ールを外皮錠とする有核錠剤（核錠剤径５罵、外皮錠径
１２調）を、有核錠剤機を用いて錠剤に成形した。Examples 1 to 4 A dry-coated tablet (core tablet diameter: 5mm, shell tablet diameter: 12mm) was prepared using a dry-coated tablet machine, with the solid drug shown in Table 1 as the core tablet and erythritol as the shell tablet. It was molded into tablets.
得られた各錠剤、及び比較のために被覆しない各固形薬
剤を、２０℃、ＲＨ９３％の空気中に２週間放置した場
合の吸水率（吸湿水分含有りを測定した結果は第１表に
示すとおシであった。The obtained tablets and each uncoated solid drug for comparison were left in air at 20°C and RH 93% for two weeks. It was Tooshi.
第 １ 表
また、各実施例で得られた被覆固形薬剤は、口にふくん
だ場合に薬剤具が殆んどなく、エリスリトールの清涼感
のある甘味を有していた。Table 1 Also, the coated solid medicines obtained in each example had almost no medicinal substance when swished in the mouth, and had the refreshing sweet taste of erythritol.
（ｃ） 発明の効果
本発明の被覆固形薬剤は、空気中に放置したときに吸湿
等の変質を殆んど起さず、化学的に安定であシ、また口
中にふくんだときに薬剤具が殆んどなく、苦味等の薬剤
味も殆んど認められないものである。(c) Effects of the Invention The coated solid drug of the present invention hardly undergoes any deterioration such as moisture absorption when left in the air, is chemically stable, and when swelled in the mouth, There are almost no ingredients, and there is almost no medicinal taste such as bitterness.
特許出願人 三菱化成工業株式会社 日研化学株式会社 、−−−一一Patent applicant: Mitsubishi Chemical Industries, Ltd. Nikken Chemical Co., Ltd. , ---11
Claims (1)
する被覆材の被覆層を形成せしめてなる被覆固形薬剤。1) A coated solid drug obtained by forming a coating layer of a coating material containing meso-erythritol as a main component on the surface of a solid drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9451288A JPH0720858B2 (en) | 1988-04-19 | 1988-04-19 | Coated solid drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9451288A JPH0720858B2 (en) | 1988-04-19 | 1988-04-19 | Coated solid drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01268628A true JPH01268628A (en) | 1989-10-26 |
| JPH0720858B2 JPH0720858B2 (en) | 1995-03-08 |
Family
ID=14112375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9451288A Expired - Lifetime JPH0720858B2 (en) | 1988-04-19 | 1988-04-19 | Coated solid drug |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0720858B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7070805B2 (en) | 1998-07-28 | 2006-07-04 | Takeda Pharmaceutical Company Limited | Rapidly disintegrable solid preparation |
| EP1736144A2 (en) | 1998-05-18 | 2006-12-27 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| JP2007045796A (en) * | 2005-08-12 | 2007-02-22 | Kao Corp | Solid preparation for oral cavity |
| JP2007284364A (en) * | 2006-04-14 | 2007-11-01 | Kao Corp | Solid preparation for oral cavities |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8914735B2 (en) | 2011-05-06 | 2014-12-16 | David H. Sitrick | Systems and methodologies providing collaboration and display among a plurality of users |
-
1988
- 1988-04-19 JP JP9451288A patent/JPH0720858B2/en not_active Expired - Lifetime
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1736144A2 (en) | 1998-05-18 | 2006-12-27 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| US7431942B2 (en) | 1998-05-18 | 2008-10-07 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| EP2263660A2 (en) | 1998-05-18 | 2010-12-22 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| US7875292B2 (en) | 1998-05-18 | 2011-01-25 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| US9901546B2 (en) | 1998-05-18 | 2018-02-27 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| US7070805B2 (en) | 1998-07-28 | 2006-07-04 | Takeda Pharmaceutical Company Limited | Rapidly disintegrable solid preparation |
| JP2007045796A (en) * | 2005-08-12 | 2007-02-22 | Kao Corp | Solid preparation for oral cavity |
| JP4719530B2 (en) * | 2005-08-12 | 2011-07-06 | 花王株式会社 | Oral solid formulation |
| JP2007284364A (en) * | 2006-04-14 | 2007-11-01 | Kao Corp | Solid preparation for oral cavities |
| US8877165B2 (en) | 2006-04-14 | 2014-11-04 | Kao Corporation | Solid preparation for oral application |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0720858B2 (en) | 1995-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4146653A (en) | Process of manufacturing dragees | |
| EP1084625B1 (en) | Flavor delivery system | |
| US5958455A (en) | Oral solid dosage forms, methods of making same and compositions thereof | |
| US4013775A (en) | Process for preparing a sugar tablet | |
| HU195731B (en) | Process for production of preparatives of stabil n-/hydroxi-ethil/-nicotinamid-nitrate | |
| WO2008050847A1 (en) | Granular preparation prevented from caking | |
| JP5201819B2 (en) | Solid composition | |
| CA1261268A (en) | Theophylline sustained release formulation | |
| TW574300B (en) | Pullulan-containing powder, manufacturing process thereof, and use thereof | |
| US4258179A (en) | Coating agents for solid medicaments | |
| JPH01268628A (en) | Coated solid drug | |
| JPH10147524A (en) | Forskolin derivative-containing oral preparation and production of medicine preparation | |
| EP0468245B1 (en) | Tablet and granulate containing MESNA as active agent | |
| CN107550866A (en) | A kind of Sebivo preparation | |
| JPH0827033A (en) | Erythritol-containing solid agent | |
| CN104069082B (en) | A kind of aspartic acid piece and preparation method thereof | |
| US2883327A (en) | Reducing the gelation of methylcellulose by the addition of a neutral, water-soluble, amino carboxylic acid and product thereof | |
| US5401519A (en) | Low calorie composite sweetener and a method of making it | |
| US5185336A (en) | Method for producing substantially pure vitamin powders | |
| CN100542526C (en) | Be used for medicinal chewing tablet of antipyretic analgesic and preparation method thereof | |
| JP4051431B2 (en) | Colloidal gold solution and method for producing the same | |
| JP3995202B2 (en) | Turmeric composition for oral use | |
| JPH01268627A (en) | Composition of immobilized drug ingredient | |
| RU2774422C1 (en) | Method for the production of a granulated sugar-containing product | |
| RU2343931C2 (en) | Pharmaceutical preparations containing amoxicillin and clavunalate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090308 Year of fee payment: 14 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090308 Year of fee payment: 14 |